Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Lignende værker

• Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
  af: Horneff, Gerd, et al.
  Udgivet: (2017)
• Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
  af: Armaroli, Giulia, et al.
  Udgivet: (2020)
• Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
  af: Horneff G, et al.
  Udgivet: (2008-09-01)
• Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
  af: Horneff, G, et al.
  Udgivet: (2008)
• Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
  af: Horneff, Gerd, et al.
  Udgivet: (2012)